Article # 11

 

Using the Ipsilateral Arm in Patients With Breast Cancer: An Evidence-Based Practice Project and Practice Change 

June 2025 • Volume 29, number 3, pages 212 - 218 • DOI: 10.1188/25.CJON.212-218 

Kathryn L. Shady 


Background: The ipsilateral arm is not used for blood pressure, phlebotomy, or IV access postmastectomy or post–lymph node removal or biopsy. The non–evidence-based practice of blanket forbidding of ipsilateral arm use can result in inaccurate calf blood pressure measurements, foot stick blood draw orders, and an increased need for tunneled central venous catheters. 

Objectives: This project piloted a practice change and allowed for the use of the ipsilateral arm in patients with breast cancer. 

Methods: The team used the Johns Hopkins Evidence-Based Practice Model to implement a practice change for hematology-oncology inpatients with breast cancer and lymph node involvement, removal, or biopsy, or mastectomy history. 

Findings: Twelve months after implementation, more than 100 patients with breast cancer participated with zero incidences of resulting lymphedema. There were no foot stick orders or calf blood pressures in patients when the ipsilateral arm was used. After 16 months, the practice change became a systemwide policy. 


Discussion Starting Points: 

Please choose two for your response:

How does this research article compare to our practice, policy and or procedure?

What are the advantages and disadvantages to the proposed recommendations in the article?

What are the advantages and disadvantages of implementing the article recommendations on your unit and/or hospital?

Was the correct method used? Why or why not?



Comments

Post a Comment

Test

Popular posts from this blog

2024 Article #1

Central  Line Patency: Management With Normal Saline Flushes for Adult Patients With Cancer  Background:  Central venous catheter (CVC) maintenance is critical in administering chemotherapy, transfusions, and high-frequency laboratory draws. Although normal saline (NS) flushes have been associated with similar incidences of irreversible port occlusions as heparin among adult patients with cancer and ports, additional research is needed regarding NS efficacy in other central line maintenance within large populations with cancer. Objectives:  The aim of this study was to analyze changes in reported CVC line patency via tissue plasminogen activator (tPA) administration rates in ports and other central lines because of an institutional switch from heparin to NS as preferred flushes in adult ambulatory patients with cancer. Methods:  Retrospective data were collected from patients with ports (3,706 prepolicy, 3,402 postpolicy) and nonport CVCs (816 prepolicy, 694 pos...
Read more

2024 Article#2

  Chlorhexidine Gluconate Baths: Supporting Daily Use to Reduce Central Line–Associated Bloodstream Infections Affecting Immunocompromised Patients Background : Chlorhexidine gluconate (CHG) has a broad-spectrum antimicrobial property that has proven to be effective in prolonging skin antisepsis and decreasing pathogens often seen in oncology units. Objectives: The aim was to reduce the incidence of central line–associated bloodstream infections in a hematology-oncology unit through the staff’s continued adherence to the institution’s protocol for CHG baths with wipes, and to identify barriers and the degree to which they interfered with optimal use of the CHG wipes. Methods: The project focused on supporting staff and nurses by providing education and training on current practices to staff and patients, and identifying barriers. Direct observation and chart audits were the approach chosen to implement the project. Findings : For the project study period, the unit had three nonpre...
Read more

2025 Article # 5

  July 2025 Hypersensitivity Reactions: Priming Practice Change to Reduce Incidence in First-Dose Rituximab Treatment August 2018 • Volume 22, number 4, pages 407 - 414 • DOI: 10.1188/18.CJON.407-414 Carissa Laudati, Caroline Clark, Andrea Knezevic, Zhigang Zhang, and Margaret Barton-Burke Background:  Strategies to reduce hypersensitivity reaction (HSR) incidence with rituximab include premedications and slow titration. Literature is lacking on the priming method used when preparing rituximab IV lines and the potential impact on HSR incidence. Objectives:  The primary objective is to evaluate HSR incidence in titrated first-dose rituximab infusions when priming IV lines with rituximab, as compared to priming with diluent. Methods:  A retrospective, comparative, descriptive study with two arms (rituximab- versus diluent-primed) was conducted. Variables were HSR incidence in relation to priming method, age, sex, diagnosis, a...
Read more